Lakewood-Amedex Pays $1.27M Cash to Retire All Series C Preferred
LABT has more than doubled off its 52-week low of $0.169 on light trading volume (0.3× avg).
Summary
Lakewood-Amedex redeemed all 127,097 Series C Preferred shares for $1,270,970 in cash, eliminating the conversion overhang and all preferred stock, but consuming a meaningful chunk of its cash on hand.
Key Events · Financing and Capital Events · LABT
-
Series C Preferred Fully Redeemed
Company redeemed all 127,097 outstanding Series C Preferred shares at $10.00 face value for an aggregate $1,270,970, paid in cash from available funds; the redemption closed November 4, 2026 and the shares were cancelled and returned to treasury.
-
Conversion Overhang Eliminated
No Series C Preferred remains outstanding, so no additional common shares are issuable on conversion, and the company reports no preferred stock and no outstanding indebtedness for borrowed money.
-
Cash Runway Reduced
The $1,270,970 was funded from cash on hand; the company's own risk disclosure notes the use of cash for the redemption may reduce liquidity and cash runway, against a $4.7M first-half net loss reported in the Q2 10-Q.
-
Restrictions and Claims Released
The redemption agreement includes a mutual release of claims relating to the Series C Preferred and related transaction documents, plus indemnification obligations of the Company in favor of Shakawe Capital LLC.
Analysis · LABT · Life Sciences
The company spent $1,270,970 of cash on hand to buy back and cancel all 127,097 Series C Preferred shares at their $10.00 face value. That removes the conversion overhang — no common shares will be issued on conversion — and clears the financing restrictions tied to the instrument, leaving no preferred stock and no borrowed debt. The trade-off is liquidity: for a clinical-stage company that reported a $4.7M first-half net loss and unremediated material weaknesses in internal controls, $1.27M is a meaningful slice of the balance sheet, and the press release itself flags that using cash for the redemption may shorten the cash runway. The redemption closed November 4, 2026, so the cash is already out the door.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LABT was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $985.8K. The 52-week trading range was $0.17 to $98.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.